{"prompt": "['Product: MK-3475', '55', 'Protocol/Amendment No.: 604-09', 'Palliative and supportive care is permitted during the course of the trial for underlying', 'medical conditions and management of symptoms. Surgery or radiotherapy for tumor control', 'is not permitted during the study; however, radiotherapy or procedures for symptom', 'management are allowed.', 'All concomitant medications received within 28 days before the first dose of trial treatment', 'and up to 30 days after the last dose of trial treatment should be recorded. Concomitant', 'medications administered more than 30 days after the last dose of trial treatment should be', 'recorded for SAEs and events of clinical interest (ECIs) as defined in Section 7.2.', 'Colony-Stimulating Factors', 'The use of colony-stimulating factors (CSFs) is highly recommended as primary prophylaxis', 'to reduce the risk of febrile neutropenia in this patient population, especially as many', 'subjects have multiple co-morbidities and advanced disease. The American Society of', 'Clinical Oncology guidelines for use of CSFs should be followed for this trial [112].', 'Antiemetic therapy', 'Antiemetic therapy should follow the Multinational Association of Supportive Care in', 'Cancer guidelines [113].', '5.5.2 Prohibited/Restricted Concomitant Medications', 'Subjects are prohibited from receiving the following therapies during Screening, Initial', 'Treatment Phase, and Second Course Phase of this trial:', 'Antineoplastic systemic chemotherapy or biological therapy', 'Immunotherapy not specified in this protocol', 'Investigational agents other than pembrolizumab', 'Surgery for tumor control', 'Radiation therapy', 'Note: Subjects are allowed to receive palliative radiotherapy for painful bone lesions.', 'Targeted external beam irradiation should not be used in the primary lung field where', 'assessment for tumor is indicated.', 'Note: PCI is permitted in subjects achieving CR or PR after Cycle 4.', 'Live vaccines within 30 days prior to the first dose of trial treatment and while', 'participating in the trial (eg, measles, mumps, rubella, varicella/zoster, yellow fever,', 'rabies, BCG, and typhoid vaccine); seasonal influenza vaccines for injection are', 'generally killed virus vaccines and are allowed; however, intranasal influenza', 'vaccines (eg, FluMistR are live attenuated vaccines and are not allowed', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '56', 'Protocol/Amendment No.: 604-09', 'Systemic glucocorticoids for any purpose other than:', 'To modulate symptoms of an AE that is suspected to have an immunologic', 'etiology', 'As required during and after PCI (subjects requiring chronic glucocorticoid', 'use following PCI should be discontinued from study therapy)', 'As needed for the prevention of emesis (as outlined in Section 5.5.1)', 'For topical use or ocular use', 'Premedication for IV contrast allergies', 'For inhalation in the management of asthma or chronic obstructive pulmonary', 'disease', 'Subjects who, in the assessment of the investigator, require the use of any of the', 'aforementioned treatments for clinical management should be removed from the trial.', 'Subjects may receive other medications that the investigator deems to be medically', 'necessary.', 'Other medications that are prohibited in this trial are discussed in Section 5.1.3.', 'There are no prohibited therapies during the Post-Treatment Follow-up Phase.', '5.6 Rescue Medications & Supportive Care', 'No rescue or supportive medications are specified to be used in this trial.', '5.6.1 Supportive Care Guidelines', 'Subjects should receive appropriate supportive care measures as deemed necessary by the', 'treating investigator. Suggested supportive care measures for the management of AEs with', 'potential immunologic etiology are outlined along with the dose modification guidelines in', 'Section 5.2.1.2.1, [Table 4]. Where appropriate, these guidelines include the use of oral or IV', 'treatment with corticosteroids, as well as additional anti-inflammatory agents if symptoms do', 'not improve with administration of corticosteroids. Note that several courses of steroid', 'tapering may be necessary as symptoms may worsen when the steroid dose is decreased. For', 'each disorder, attempts should be made to rule out other causes such as metastatic disease or', 'bacterial or viral infection, which might require additional supportive care. The treatment', 'guidelines are intended to be applied when the investigator determines the events to be', 'related to pembrolizumab.', 'Note: If after evaluation of the event, it is determined not to be related to pembrolizumab,', 'the investigator does not need to follow the treatment guidance. It may be necessary to', 'perform conditional procedures such as bronchoscopy, endoscopy, or skin photography as', 'part of evaluation of the event.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}